Insider · CIK 0001592380

Thorp Clay

Reports to the SEC for 4 companies · ALPHARETTA, GA

sec.gov

Transactions

Companies

Filings

CIK

0001592380

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-02-24	CLSDQClearside Biomedical, Inc.P Purchase	Director	PPurchase	+15K sh	$0.92	+$13.8K	176,141
2024-06-20	CLSDQClearside Biomedical, Inc. · Stock Option (right to buy)A Award	Director	AAward	+45K sh	—	—	45,000
2023-09-25	CLSDQClearside Biomedical, Inc.P Purchase	Director	PPurchase	+10K sh	$0.86	+$8,600	40,522
2023-06-22	CLSDQClearside Biomedical, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-05-19	PhaseBio Pharmaceuticals IncM Exercise/Conversion	Director	MExercise/Conversion	+3,750 sh	—	—	36,693
2023-05-19	PhaseBio Pharmaceuticals IncRestricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	+3,750 sh	—	—	0
2022-12-21	CLSDQClearside Biomedical, Inc.P Purchase	Director	PPurchase	+14K sh	$1.02	+$14.3K	30,522
2022-12-15	CLSDQClearside Biomedical, Inc.J Other	Director	JOther	−1.41M sh	—	—	3,545,040
2022-12-15	CLSDQClearside Biomedical, Inc.J Other	Director	JOther	+8,522 sh	—	—	16,522
2022-06-22	CLSDQClearside Biomedical, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2022-05-19	PhaseBio Pharmaceuticals IncNon-employee Director Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2022-05-19	PhaseBio Pharmaceuticals IncRestricted Stock UnitsA Award	Director	AAward	+3,750 sh	—	—	3,750
2022-05-17	Vigil Neuroscience, Inc.P Purchase	Director	PPurchase	+14.9K sh	$2.97	+$44.2K	1,556,030
2022-05-16	Vigil Neuroscience, Inc.P Purchase	Director	PPurchase	+21.8K sh	$2.76	+$60.2K	1,541,137
2022-03-28	Vigil Neuroscience, Inc.P Purchase	Director	PPurchase	+3,000 sh	$7.20	+$21.6K	3,000
2022-01-11	Vigil Neuroscience, Inc.Series A Preferred StockC Conversion	Director	CConversion	−2.55M sh	—	—	0
2022-01-11	Vigil Neuroscience, Inc.Series B Preferred StockC Conversion	Director	CConversion	−927K sh	—	—	0
2022-01-11	Vigil Neuroscience, Inc.C Conversion	Director	CConversion	+1.25M sh	—	—	1,254,335
2022-01-11	Vigil Neuroscience, Inc.P Purchase	Director	PPurchase	+265K sh	$14.00	+$3.71M	1,519,335
2021-08-18	PhaseBio Pharmaceuticals IncP Purchase	Director	PPurchase	+10K sh	$3.00	+$30K	32,943
2021-06-10	CLSDQClearside Biomedical, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2021-06-03	PhaseBio Pharmaceuticals IncNon-employee Director Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000
2021-02-10	CLSDQClearside Biomedical, Inc.S Sale	Director	SSale	−32.9K sh	$4.43	−$146K	3,433,521
2021-02-10	CLSDQClearside Biomedical, Inc.S Sale	Director	SSale	−32.9K sh	$4.43	−$146K	4,951,547
2020-11-24	PhaseBio Pharmaceuticals IncP Purchase	Director	PPurchase	+2,000 sh	$3.50	+$7,000	22,943
2020-11-23	PhaseBio Pharmaceuticals IncP Purchase	Director	PPurchase	+3,000 sh	$3.67	+$11K	20,943
2020-11-16	PhaseBio Pharmaceuticals IncJ Other	Director	JOther	−52.4K sh	—	—	0
2020-11-16	PhaseBio Pharmaceuticals IncJ Other	Director	JOther	+2,144 sh	—	—	17,943
2020-11-16	PhaseBio Pharmaceuticals IncJ Other	Director	JOther	+10.6K sh	—	—	15,432
2020-06-18	CLSDQClearside Biomedical, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2020-06-03	PhaseBio Pharmaceuticals IncNon-employee Director Stock Option (right to buy)A Award	Director	AAward	+16K sh	—	—	16,000
2019-11-22	CLSDQClearside Biomedical, Inc.A Award	Director	AAward	+1.52M sh	$1.05	+$1.6M	4,984,420
2019-07-01	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−2,014 sh	$14.00	−$28.2K	1,818,638
2019-07-01	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−180 sh	$14.00	−$2,520	162,890
2019-07-01	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−255 sh	$14.00	−$3,570	52,397
2019-07-01	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−459 sh	$14.00	−$6,426	415,959
2019-06-20	CLSDQClearside Biomedical, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-06-18	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−277 sh	$14.00	−$3,878	1,820,656
2019-06-18	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−25 sh	$14.00	−$350	163,074
2019-06-18	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−35 sh	$14.00	−$490	52,655
2019-06-18	PhaseBio Pharmaceuticals IncS Sale	Director	SSale	−63 sh	$14.00	−$882	416,418
2019-05-09	PhaseBio Pharmaceuticals IncNon-employee Director Stock Option (right to buy)A Award	Director	AAward	+11K sh	—	—	11,000
2019-02-27	PhaseBio Pharmaceuticals IncEmployee Stock Option (right to buy)A Award	Director	AAward	+36K sh	—	—	36,000
2018-12-06	CLSDQClearside Biomedical, Inc.P Purchase	Director	PPurchase	+8,000 sh	$1.36	+$10.9K	8,000
2018-12-04	PhaseBio Pharmaceuticals IncP Purchase	Director	PPurchase	+4,000 sh	$3.13	+$12.5K	15,799
2018-10-22	PhaseBio Pharmaceuticals IncC Conversion	Director	CConversion	+52.7K sh	—	—	52,690
2018-10-22	PhaseBio Pharmaceuticals IncC Conversion	Director	CConversion	+1.68M sh	—	—	1,683,420
2018-10-22	PhaseBio Pharmaceuticals IncP Purchase	Director	PPurchase	+138K sh	$5.00	+$688K	1,820,933
2018-10-22	PhaseBio Pharmaceuticals IncC Conversion	Director	CConversion	+151K sh	—	—	150,612
2018-10-22	PhaseBio Pharmaceuticals IncP Purchase	Director	PPurchase	+12.5K sh	$5.00	+$62.4K	163,099

Recent filings

Accepted (ET)
Feb 244
Thorp Clay0001415889-25-005325
SEC(opens sec.gov)
Jun 214
Thorp Clay0001415889-24-017821
SEC(opens sec.gov)
Sep 254
Thorp Clay0001209191-23-050480
SEC(opens sec.gov)
Jun 234
Thorp Clay0001209191-23-039427
SEC(opens sec.gov)
May 194
Thorp Clay0001169245-23-000032
SEC(opens sec.gov)
Dec 214
Thorp Clay0001209191-22-062338
SEC(opens sec.gov)
Dec 194/A
Thorp Clay0001209191-22-062044
SEC(opens sec.gov)
Dec 194
Thorp Clay0001209191-22-062045
SEC(opens sec.gov)
Jun 244
Thorp Clay0001209191-22-039220
SEC(opens sec.gov)
May 204
Thorp Clay0001169245-22-000065
SEC(opens sec.gov)
May 174
Thorp Clay0000899243-22-018491
SEC(opens sec.gov)
Mar 284
Thorp Clay0000899243-22-012485
SEC(opens sec.gov)
Jan 114
Thorp Clay0000899243-22-001658
SEC(opens sec.gov)

Companies

Address

C/O CLEARSIDE BIOMEDICAL, INC. 900 NORTH POINT PARKWAY, SUITE 200

ALPHARETTA, GA, 30005